Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858811 | 0.82 | KDM4E (0.33) | KDM4E | |
| SCHEMBL12628765 | 0.79 | MAOA (0.39) | KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL12628821 | 0.78 | KDM4E (0.31) | KDM4E | |
| SCHEMBL12628813 | 0.73 | — | — | |
| SCHEMBL12628788 | 0.72 | MAPK14 (0.32) | — | |
| SCHEMBL12401228 | 0.70 | SMN1; SMN2 (0.37) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL12628793 | 0.68 | KDM4E (0.30) | KDM4E | |
| SCHEMBL30142226 | 0.63 | KDM4E (0.69) | KDM4E | |
| SCHEMBL12758099 | 0.61 | — | — | |
| SCHEMBL12401236 | 0.61 | CD274 (0.40) | KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673890-B2 | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-8673890-B2 | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-8673890-B2 | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | F2R, F2RL1, F2RL3 | KDM4E 4723/4885L3MBTL1 3531/4885SMN1; SMN2 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.